Aug 07, 2026 —
Aspen Neuroscience announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to sasineprocel, also known as ANPD001, its lead investigational autologous iPSC-derived cell therapy for Parkinson’s disease.
Sasineprocel previously received FDA Fast Track designation. RMAT designation provides opportunities for increased FDA interaction and expedited development support, including potential eligibility for priority review and accelerated approval pathways for qualifying regenerative medicine therapies.
The designation is based on results from Aspen’s ongoing ASPIRO Phase 1/2a trial, which the company said has demonstrated encouraging early clinical activity and a favorable safety profile.
ASPIRO is an open-label, multicohort, multicenter study evaluating the safety, tolerability, and activity of surgical delivery of autologous dopaminergic neuron precursor cells, or DANPCs, into the putamen, a brain region where restoration of dopamine signaling is needed in Parkinson’s disease.
Sasineprocel is designed as a single-dose, autologous iPSC-based cell therapy. The treatment is created from a patient’s own cells obtained through a small skin punch biopsy. These cells are reprogrammed into induced pluripotent stem cells, then differentiated into dopaminergic neuron precursor cells.
The proprietary cell composition is delivered through image-guided administration to the putamen, with the goal of replacing lost dopaminergic neurons and reconstructing neural circuitry affected by Parkinson’s disease progression.
Aspen said the therapy is designed to establish a biologically active cellular microenvironment that supports engraftment, survival, and functional integration of transplanted cells, with the aim of achieving durable clinical benefit and potentially slowing or halting disease progression.
Because sasineprocel is autologous and uses a patient’s own cells, Aspen noted that immunosuppression is not required, unlike donor-derived allogeneic cell therapy approaches.
The RMAT designation marks an important regulatory milestone for Aspen’s personalized regenerative medicine platform and supports continued development of sasineprocel as a potential disease-modifying cell therapy for Parkinson’s disease.
